221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].


Participation Guidelines

Ages: 50 - 85 years

Gender: Both


Biogen Idec, Inc.

Dates: 11/06/2015 - 02/01/2020

Last Updated: 12/15/2015

Study HIC#: 1505015817

Get Involved

For more information about this study, contact:
Melinda Leigh Becker

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Christopher H Van Dyck

Principal Investigator

Sub-Investigators